Home > Healthcare > Anti-retroviral Drugs Market

Anti-retroviral Drugs Market Trends

Report ID: GMI8298
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Anti-retroviral Drugs Market Trends

The market is expanding owing to new drug approvals and product launches. For instance, in December 2021, the U.S. FDA authorized Apretude used as pre-exposure prophylaxis (PrEP) to lower the risk of HIV infection acquired via sexual activity in adults and adolescents who are at-risk. Therefore, such approvals and new drug launches are impelling the growth of the market.

Furthermore, pharmaceutical companies investing in research and development to create more effective and tolerable anti-retroviral drugs is propelling the market growth. This includes developing new formulations, combination therapies, and long-acting drugs to improve patient adherence and outcomes. Thus, aforementioned factors are anticipated to accelerate the market expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Anti-retroviral drugs market size was USD 29.1 billion in 2023 and is expected to register 4.2% CAGR from 2024-2032 owing to the increased investment in research and development, and the emergence of multiple generic drug alternatives worldwide.

The multi-class combination segment reached USD 7.9 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to the growing burden of HIV and new drug approvals.

Anti-retroviral drugs market from the branded segment held 67.2% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to ongoing advancements and innovation in the development, distribution, and utilization of branded antiretroviral drugs.

AbbVie Inc., Bristol-Myers Squibb Company, Cipla, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc., Johnson and Johnson, Merck & Co, Inc., Pfizer Inc., and Viatris Inc., are some of the major anti-retroviral drugs companies worldwide.